Advertisement
"Physicians demand large improvements in efficacy," said Vickie Lai,analyst at Decision Resources. "A therapy that induces remission in morepatients than Remicade must induce remission in at east 40 percent ofpatients, an improvement of more than 40 percent over Remicade's rate ofinduction. Physicians do not expect a reduction in side effects, however, aslong as the agent offers greater efficacy and more convenient administration.Approximately 75 percent of respondents we surveyed for the report mandatethat a new drug be self-administered (either orally or via subcutaneousinjections)."
Advertisement
About Lack of Alternatives to Invasive Surgery Signals Opportunity forDrug Makers: An Acute Ulcerative Colitis Study
Lack of Alternatives to Invasive Surgery Signals Opportunity for DrugMakers: An Acute Ulcerative Colitis Study covers the current and future stateof the acute ulcerative colitis drug market. The report includes thefollowing:
The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a worldleader in market research publications, advisory services, and consultingdesigned to help clients shape strategy, allocate resources, and master theirchosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- More than 3,000 physician responses that define drug attributes driving prescription now and in the future. -- Clinical end point tradeoffs that are most influential to physicians. -- Areas of unmet need with highest potential. -- Benchmark trial results for specific drug opportunities. -- Patient share potential for emerging therapies and target product profiles. -- Decision Resources proprietary analysis of commercial factors that accelerate or constrain a drug's market potential. -- Promotion: DTC spend, detailing intensity. -- Reimbursement: formulary tier, prior approval restriction, quantity limits. -- Labeling: black box warnings, approved patient segments, contraindications. -- Competition: order of entry, pricing, generic entry, pipeline sales forecast. -- Medical practice: decision trees, treating physician type, line of therapy. -- Comparisons of the key clinical attributes of current and emerging therapies in the areas of efficacy, safety, and delivery. -- Analysis and supporting data that identify the clinical "Gold Standard" now and over the next ten years. -- Key insights as to which clinical end points have the greatest influence on physician decision-making.
SOURCE Decision Resources, Inc.
